Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous epstein-barr virus-specific cytotoxic t lymphocytes (CHU de Nantes)
- Development stage
- Unknown
- Lead developer
- CHU de Nantes
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-specific CTLs) is an investigational adoptive cell therapy developed by Centre Hospitalier Universitaire de Nantes (Nantes University Hospital). The therapy involves the ex vivo expansion of a patient's own T lymphocytes to specifically target and eliminate cells infected with the Epstein-Barr virus (EBV), focusing on antigens such as EBNA1, LMP1, and LMP2A. The biological rationale is based on the hypothesis that a deficiency in CD8+ T cell-mediated immune surveillance of EBV allows EBV-infected autoreactive B cells to accumulate and drive the pathogenesis of multiple sclerosis (MS). By restoring this immune surveillance, the therapy aims to reduce disease activity in patients with MS and clinically isolated syndrome (CIS).
- Other names
- autologous EBV-specific CTLsEBV-specific CTLsEBV-specific cytotoxic T lymphocytes
02
Targets
pMHC (Peptide-MHC complex family)pMHC-I (Peptide–MHC class I complex)Epstein-Barr virus Latent Membrane Protein 2A-derived peptide–Human Leukocyte Antigen complexes
Beyond the preview
Go deeper on autologous epstein-barr virus-specific cytotoxic t lymphocytes (CHU de Nantes).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous epstein-barr virus-specific cytotoxic t lymphocytes (CHU de Nantes).